Navigation Links
Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
Date:1/30/2008

MELBOURNE, Australia, Jan. 30 /PRNewswire-FirstCall/ -- Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced results of a pre-clinical study demonstrating that the combination of its APA- 01 product candidate and the statin atorvastatin (Lipitor(TM)) significantly reduced serum lipids and inflammatory proteins involved in the development of atherosclerosis.

Study Design

The purpose of the study was to determine whether a combination of the statin drug atorvastatin and APA-01 could reduce serum lipids, inhibit atherosclerotic lesion progression and reduce proinflammatory cytokines and other biomarkers of inflammatory disease more effectively than the statin alone.

Studies were performed in ApoE mice, animals that spontaneously form atherosclerotic plaques and represent a well-established model of human atherogenic hyperchosterolemia.

During the first 16-weeks of this 24-week study, all animals in the experimental group were maintained on a standard diet, followed by an eight week treatment period in which this diet was supplemented with 21% fat and 0.15% cholesterol, an atherogenic diet expected to accelerate atherosclerotic progression. All animals in the experimental groups received drug treatment in both their normal and high-fat diets at various dosing regiments throughout the 24-week study. Control group animals received no drug treatment and were maintained on either the same diet as the treatment groups or on a standard diet.

Study Results

Effects on Serum Lipids

The study results indicated that among the animals treated with the APA-01 and atorvastatin combination, total cholesterol levels fell by up to an additional 12% compared to those animals treated with atorvastatin alone. Total HDL-C (good cholesterol) levels increased by up to 37% in combination drug-treated animals, while LDL-C (bad cholesterol) levels were further reduced by up to 24% with the combination,
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , NOVATO, Calif., Nov. 30 /PRNewswire-FirstC...N ) announced today that the Food and Drug Adminis...for 3,4-diaminopyridine (3,4-DAP), amifampridine p...Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has pre...U. Also, in October 2009, the Committee for Medic...
(Date:11/30/2009)... , BOSTON and COPENHAGEN, Nov. 30 /PRNewsw...announced today that the Harvard Medical School IC...ecognized as a MicroRNA Screening Center of Excell...dical School, and associated hospitals and institu...cule and RNAi libraries. ,, MicroRNAs are a nov...
(Date:11/30/2009)... , AMSTERDAM, N... world,s,leading publisher of scientific, medical ...ed a major re-launch of Embase, its comprehensive ...dexed records from more than 7,000,active, peer re... a key role in the advancement of new biomedical,a...
(Date:11/27/2009)... , DURHAM, N.C., Nov. 27 /PRNewswire/ ... will initiate water-soluble carbon nanotube-based...The water-soluble carbon nanotubes, which have fun...ation with cancer drugs, was developed in partners... conjugated carbon nanotubes serves as a drug deli...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...Call/ -- China Technology,Development Group Corpor...rovider of clean and renewable energy products and...ina, today is pleased to announce that it has,appo...") to act as its,independent auditor for the fisca...ry of the service term of Friedman LLP ("Friedman"...
...asdaq: MDVN ) today reported on its financial res...mber 31, 2007., "In 2007 we continued our track r...ent across our entire portfolio, and we are please...t candidate in confirmatory,Phase 3 development," ...utive officer of Medivation. "We remain committed ...
...of Pulse CO-Oximetry as a way to, protect the li...of CO Poisoning, IR...inventor of Pulse CO-Oximetry and Measure-Through ... today that the National Fire Protection,Associati...ing by Pulse,CO-Oximetry as part of a new national...
Other Biology Technology:China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor 2Medivation Reports Year-End 2007 Financial Results and Pipeline Progress 2Medivation Reports Year-End 2007 Financial Results and Pipeline Progress 3Medivation Reports Year-End 2007 Financial Results and Pipeline Progress 4Medivation Reports Year-End 2007 Financial Results and Pipeline Progress 5Medivation Reports Year-End 2007 Financial Results and Pipeline Progress 6Medivation Reports Year-End 2007 Financial Results and Pipeline Progress 7National Fire Protection Association (NFPA) Sets New National Standard for CO Screening by Pulse CO-Oximetry(TM) 2National Fire Protection Association (NFPA) Sets New National Standard for CO Screening by Pulse CO-Oximetry(TM) 3National Fire Protection Association (NFPA) Sets New National Standard for CO Screening by Pulse CO-Oximetry(TM) 4
(Date:11/30/2009)...iversity researchers Ron Falta and Larry Murdoch h...Agency grant to study the safe storage of carbon d... the earth,s surface. , With carbon dioxide emis... leading cause of global warming, geologic storage...ves for reducing emissions using current technolog...
(Date:11/30/2009)...9) Scientists and engineers from two of the natio...come together Dec. 7 with leading academicians to ...ood. , Much like moving oil through a pipeline, ...systems need clean, well-functioning pipes (or blo...nction efficiently. Both industries also are cruci...
(Date:11/30/2009)...er early bird registration rates and register onli...010 at http://www.iofwco-ecceo10.org/ , WHAT:...ational Osteoporosis Foundation (IOF) and the Euro...Osteoporosis and Osteoarthritis (ESCEO). More than...cted to attend. The exciting scientific programme ...
Breaking Biology News(10 mins):Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3Pelosi Remarks Following House Democrats Meeting with President Obama 60895 1Pelosi Remarks Following House Democrats Meeting with President Obama 60895 2PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 60893 1PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 60893 2PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 60893 3Prodromal Symptoms Warn of Hereditary Angioedema Attacks Give Patients Time to Start Therapy and Decrease Morbidity 6069 1Prodromal Symptoms Warn of Hereditary Angioedema Attacks Give Patients Time to Start Therapy and Decrease Morbidity 6069 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks Give Patients Time to Start Therapy and Decrease Morbidity 6069 3
...niversity of Sheffield has shown that major oil sp... impact on populations of British sea birds than w...Tim Birkhead from the Department of Animal and Pla...for the first time that major oil spills double th...ven though the pollution occurs hundreds of miles ...
...k CNS infectionA single molecular anchor that allo...the key to treating many types of bacterial mening... School of Medicine study has found. , By blockin...y be able to find a way to stave off the most comm... and a major cause of childhood death and disabili...
...uel disease. Left untreated, prostate cancer cells...form fracture-prone tumors that are extremely pain...rostate cancer die with metastatic disease in thei... migrating prostate cancer cells set up housekeepi...ns characteristic of prostate cancer. , Now, new ...
Other Biology News:Oil spills and climate change double the mortality rate of British seabirds 2Researchers identify molecular anchor that allows bacterial invasion of central nervous system 2Researchers identify molecular anchor that allows bacterial invasion of central nervous system 3Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 2Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors 3
...ease III digests duplex DNA in a 3'-> 5' direction...stretches of single-stranded DNA. Under defined re...III proceeds at a uniform rate yielding predictabl...onucleolytic excision of deoxyribonucleotides by E...
RNase H from Roche Applied Science
Goat Anti-Human Haptoglobin Polyclonal Antibody, Unconjugated from Abcam
Rat Anti-STENOTROPHOMONAS MALTOPHILIA Polyclonal Antibody, Unconjugated from AbD Serotec
Biology Products: